Soft Tissue Sarcoma Clinical Trials

None

UPCC 02521 A Randomized Phase II Trial of Cabozantinib Combined with PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

0.0

PHASE I TRIAL OF AUTOLOGOUS T CELLS ENGINEERED TO EXPRESS NY-ESO-1 TCR AND GENE EDITED TO ELIMINATE ENDOGENOUS TCR AND PD-1

This is a Phase 1 first-in-human trial proposed to determine the safety profile and manufacturing feasibility of a single infusion of NYCE T cells on adult patients with myeloma, synovial sarcoma, and myxoid/round cell liposarcoma, and melanoma who have relapsed or refractory tumors expressing NY-ESO-1 antigen.

EFICACIA Y SEGURIDAD DE UN MEDICAMENTO INYECTABLE UNA VEZ A LA SEMANA EN PARTICIPANTES CON SOBREPESO U OBESIDAD. (REDEFINIR 1)

Este es un estudio de prueba de concepto multicéntrico, aleatorizado, doble ciego, controlado con placebo, de 2 brazos, de grupos paralelos.

Integrated biomarker PET/CT imaging trial for assessing hypoxia in soft tissue sarcomas using a novel PET/CT tracer

This is a pilot study. Subjects with primary soft tissue sarcoma of the extremities may be eligible for this study. Subjects may participate in this study if they are at least 18 years of age.

UPCC 10519 / I5B-MC-Y001: An Open-Label Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma

The purpose of this program is to allow patients who, in consultation with their treating physician, feel it is in their best interest to continue to receive olaratumab. Only patients with soft tissue sarcoma who are already being treated with olaratumab may enter this program.

Estudio aleatorizado, doble ciego, paralelo y controlado con placebo sobre la eficacia, la seguridad y la tolerabilidad de dupilumab en pacientes adultos con esofagitis eosinofílica activa

Este es un estudio de prueba de concepto multicéntrico, aleatorizado, doble ciego, controlado con placebo, de 2 brazos, de grupos paralelos.